Cerluten

Cerluten is a peptide complex bioregulator classified as a Cytomax for brain tissue in the Khavinson system. It is manufactured by extraction from brain tissue of young calves under 12 months old using the patented Khavinson process. Constituent peptides have molecular weights up to approximately 10 kDa.

The Khavinson bioregulator program produced two parallel compound classes. Cytomaxes are organ-specific peptide extracts containing heterogeneous mixtures of peptides. Cytogens are short synthetic peptides designed to reproduce single defined active sequences. For brain tissue, Cerluten is the contemporary Cytomax preparation and Cortagen (Ala-Glu-Asp-Pro / AEDP tetrapeptide) is the synthetic Cytogen.

The broader Khavinson brain-peptide program also includes Cortexin, an earlier bovine brain extract preparation with longer Russian clinical history as a parenteral pharmaceutical. Cerluten and Cortexin overlap in source material and proposed mechanism but differ in formulation, regulatory status, and clinical use patterns. The standard contemporary Russian protocol uses Cortagen as the initial-phase synthetic Cytogen followed by Cerluten as the extended-support Cytomax.

The Evidence

The compound-specific evidence base consists of:

• Russian-institution observational studies in elderly populations with subjective cognitive complaints
• Use in post-stroke rehabilitation protocols in Russian medical centers
• Reports of adjunct use in mild cognitive impairment and age-related cognitive decline
• Inclusion in broader Khavinson geroprotective protocols
• Animal model data on CNS aging markers and neuroprotection in stress models

Independent Western confirmation is absent. PubMed indexing for Cerluten returns predominantly Khavinson-affiliated publications and Russian-language clinical observation reports. No registered ClinicalTrials.gov study exists.

The compound's clinical claims sit in an area with substantial evidence-based pharmaceutical alternatives. For symptomatic Alzheimer's disease, cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine have decades of Phase 3 evidence. For early symptomatic AD, amyloid-targeting antibodies (lecanemab, donanemab) provide pathology-modifying evidence. For post-stroke recovery, multidisciplinary rehabilitation has substantial evidence. Cerluten sits outside this evidence-based clinical framework.

Regulatory and Legal Status

FDA. No approval. Not on bulk drug substances list.

EMA. No approval.

Russia. Registered as a biologically active dietary supplement.

WADA. Not on 2026 Prohibited List.

The proposed mechanism follows the Khavinson short-peptide bioregulation model with brain-tissue specificity.

Cellular entry and DNA interaction. Short peptides from the Cerluten complex are hypothesized to enter neurons and glial cells, reach the nucleus, and modulate gene expression. The Khavinson model treats this as the basis for tissue-selective effects.

Proposed downstream effects. Khavinson group publications describe brain peptide complex effects on:

• Modulation of inflammatory and stress-response gene expression in CNS tissue
• Effects on neurotrophic factor expression markers
• Anti-oxidant effects in neural homogenates
• Preservation of neuronal morphology in animal aging models
• Effects on cerebral blood flow markers in some animal studies

Specific gene-expression changes have not been mapped in independent transcriptomic studies. Tissue-specificity claims rest on functional observations in animal models and the broader Khavinson framework.

Comparison with established CNS pharmacology. Pharmaceutical approaches to cognitive aging and neurodegenerative disease work through well-characterized mechanisms. Cholinesterase inhibitors increase synaptic acetylcholine. Memantine blocks glutamate NMDA receptor overactivation. Amyloid-targeting antibodies clear amyloid plaques. The Khavinson proposed mechanism (CNS gene-expression modulation by short peptides) is not validated by independent neuroscience research and is not a class targeted by approved pharmaceuticals.

Pharmacokinetics. Bovine-origin peptide complexes face the same challenge as any orally administered peptide: gut hydrolysis to free amino acids and short fragments. The blood-brain barrier provides an additional substantial obstacle to CNS effects of orally administered peptides. The Khavinson framework proposes signaling at the gut-mucosa interface propagated systemically through neural and humoral pathways rather than requiring intact peptide delivery to brain tissue. Direct measurement of plasma or CSF peptide levels after Cerluten administration is not published.

Human pharmacokinetic data is not published.

Russian-institution observational data and manufacturer documentation report:

• Subjective improvement in memory and concentration in elderly populations
• Reduction in subjective cognitive fatigue scores
• Possible adjunct effects in post-stroke recovery protocols
• Subjective mood improvements in some users
• Reduction in subjective markers of nervous system fatigue
• Inclusion in protocols for chronic stress recovery

Research-chemical user reports outside Russia describe variable individual cognitive improvements, often as part of broader nootropic stacks. Reports are anecdotal, uncontrolled, and not verified for vial identity. Subjective cognitive improvements from supplement use are particularly susceptible to placebo effects, expectation bias, and parallel lifestyle changes.

None of these effects has been quantified in a Western-standard placebo-controlled trial.

No standardized human dosing protocol supported by independent pharmacokinetic data exists for Cerluten.

The Russian retail product is dosed as 1 to 2 capsules once or twice daily during meals for a 30-day course, repeated 2 to 3 times per year. Each capsule contains approximately 10 mg of active brain peptide complex.

The course-and-cycle pattern is standard Khavinson protocol. Optimal cycle spacing for Cerluten has not been independently validated.

Subcutaneous research-chemical use is uncommon for Cytomaxes. Injection of bovine-derived heterogeneous peptide mixtures carries higher infectious and immunogenicity risk than injection of single defined synthetic peptides.

The Khavinson bioregulator class has a benign published adverse-event profile. Russian manufacturer documentation for Cerluten lists individual intolerance, pregnancy, lactation, and age below 14 years as contraindications.

The bovine brain origin creates a distinct safety profile compared with synthetic Cytogens. Theoretical concerns specific to Cerluten include:

• Contamination risk from bovine brain source tissue
• Theoretical prion-related concerns from bovine brain-derived products specifically (brain tissue carries higher theoretical prion risk than other bovine tissues)
• Potential immunogenicity from foreign-protein exposure
• Endotoxin risk in any injectable forms

The Russian manufacturer describes sourcing standards and quality controls. Third-party verification at Western regulatory standards has not been performed. The bovine brain origin warrants particular consideration of contamination risk compared with other bovine-tissue Cytomaxes.

Long-term human safety data with controlled endpoints does not exist.

Theoretical concerns specific to chronic CNS-targeted gene-expression modulation:

• Effects on seizure threshold with chronic neuroactive compound use are uncharacterized
• Drug-drug interactions with cholinesterase inhibitors, memantine, antidepressants, and other CNS-active medications have not been formally studied
• Effects in patients with active neurodegenerative disease (Alzheimer's, Parkinson's, Lewy body dementia) have not been evaluated
• Effects in patients with epilepsy or seizure disorders have not been characterized

Within the Khavinson system, Cerluten is the brain Cytomax. The standard Cytogen-then-Cytomax sequence pairs Cortagen as the synthetic initial-phase compound with Cerluten as the extended-support Cytomax.

For broader CNS bioregulator stacks, Cerluten combines with:

• Cortexin (related earlier brain peptide preparation with parenteral pharmaceutical history)
• Pinealon (EDR tripeptide for neural and pineal-axis support)
• Endoluten (pineal Cytomax) for combined CNS-pineal coverage
• Epitalon (AEDG pineal Cytogen for longevity and circadian effects)

For broader geroprotective protocols, Cerluten joins organ-specific bioregulators in comprehensive aging protocols. No combined-stack human trial has been published.

External evidence-based comparators in cognitive medicine have substantial Phase 3 evidence bases:

• Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for symptomatic Alzheimer's disease
• Memantine for moderate-to-severe Alzheimer's disease
• Amyloid-targeting antibodies (lecanemab, donanemab) for early symptomatic Alzheimer's disease
• Comprehensive stroke rehabilitation (physical therapy, occupational therapy, speech therapy) for post-stroke recovery
• Lifestyle interventions (exercise, social engagement, cognitive training, sleep optimization, Mediterranean-style diet) for age-related cognitive decline

Cerluten has no comparable evidence base for any specific neurological indication. Its role, if any, is as an investigational supplement rather than as therapy for diagnosed CNS disease.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.